NO20051037L - Totalsyntese av myriaporoner - Google Patents

Totalsyntese av myriaporoner

Info

Publication number
NO20051037L
NO20051037L NO20051037A NO20051037A NO20051037L NO 20051037 L NO20051037 L NO 20051037L NO 20051037 A NO20051037 A NO 20051037A NO 20051037 A NO20051037 A NO 20051037A NO 20051037 L NO20051037 L NO 20051037L
Authority
NO
Norway
Prior art keywords
substituted
unsubstituted
group
aralkyl
aryl
Prior art date
Application number
NO20051037A
Other languages
English (en)
Inventor
Andres Francesch
Carmen Cuevas Marchante
Marta Perez Lvarez
Carlos Del Pozo Losada
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of NO20051037L publication Critical patent/NO20051037L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

Forbindelser av generell formel (I) eller et farmasøytisk akseptabelt salt, derivat, prolegemiddel eller stereoisomer derav er tilveiebrakt: hvori substituentgruppene definert ved R, er hver uavhengig valgt fra gruppen bestående av H, SiR'3, SOR, SO2X, e(=0)R, e(=0)OR', e(=0)NR', substltiiert eller usubstittiert alkyl, substituert eller usubstittiert alkenyl, substituert eller usubstituert alkynyl, aryl, heteroaryl eller aralkyl; gruppen R er valgt fra substituert eller usubstituert alkyl, substituert eller usubstituert alkenyl, substituert eller usubstituert alkynyl, aminoalkyl, aryl, aralkyl og heterosykliske grupper; og gruppen R" er valgt fra gruppen bestående av H, OH, OR, OeORI, SH, SR, SOR, SO2R, NO2, NH2, NHR, N(R)2, NHeOR, N(eOR)2, NHSO2R, eN, halogen, e(=0)H, e(=0)R, eOzH, e02R, eH20R, substitiiert eller usubstituert alkyl, substituert eller usubstituert haloalkyl, substituert eller usubstituert alkenyl, substituert eller usubstituert alkyliden, substituert eller usubstituert alkynyl, substituert eller usubstituert atyl, substituert eller usubstituert aralkyl og substituert eller usubstituert heteroaromatisk; forutsatt at forbindelsen ikke er forbindelse 1, 3 eller 4 ifølge US patent 5 514 708. Forbindelsene har antitumoraktivitet. En synteserute er også tilveiebrakt.
NO20051037A 2002-07-30 2005-02-25 Totalsyntese av myriaporoner NO20051037L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0217638.6A GB0217638D0 (en) 2002-07-30 2002-07-30 Total synthesis of myriaporones
PCT/GB2003/003327 WO2004011458A1 (en) 2002-07-30 2003-07-30 Total synthesis of myriaporones

Publications (1)

Publication Number Publication Date
NO20051037L true NO20051037L (no) 2005-04-13

Family

ID=9941374

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051037A NO20051037L (no) 2002-07-30 2005-02-25 Totalsyntese av myriaporoner

Country Status (20)

Country Link
US (1) US7521478B2 (no)
EP (1) EP1532139B1 (no)
JP (1) JP2006504659A (no)
KR (1) KR20050053599A (no)
CN (1) CN100390167C (no)
AT (1) ATE364603T1 (no)
AU (1) AU2003248984A1 (no)
CA (1) CA2494532A1 (no)
DE (1) DE60314426T2 (no)
DK (1) DK1532139T3 (no)
ES (1) ES2289337T3 (no)
GB (1) GB0217638D0 (no)
IL (1) IL166484A0 (no)
MX (1) MXPA05001176A (no)
NO (1) NO20051037L (no)
NZ (1) NZ537678A (no)
PT (1) PT1532139E (no)
RU (1) RU2328492C2 (no)
SI (1) SI1532139T1 (no)
WO (1) WO2004011458A1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514708A (en) * 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
HRP970141A2 (en) * 1997-03-12 1999-02-28 Banić-Tomaueić Zrinka New secomacrolydes of erythromicin a, and a process for the preparation thereof

Also Published As

Publication number Publication date
MXPA05001176A (es) 2005-09-12
DE60314426D1 (de) 2007-07-26
KR20050053599A (ko) 2005-06-08
NZ537678A (en) 2006-11-30
IL166484A0 (en) 2006-01-15
CN100390167C (zh) 2008-05-28
ES2289337T3 (es) 2008-02-01
EP1532139B1 (en) 2007-06-13
CA2494532A1 (en) 2004-02-05
US20060084819A1 (en) 2006-04-20
US20080103320A2 (en) 2008-05-01
RU2005105329A (ru) 2005-08-27
JP2006504659A (ja) 2006-02-09
RU2328492C2 (ru) 2008-07-10
EP1532139A1 (en) 2005-05-25
PT1532139E (pt) 2007-09-20
GB0217638D0 (en) 2002-09-11
US7521478B2 (en) 2009-04-21
ATE364603T1 (de) 2007-07-15
CN1684956A (zh) 2005-10-19
SI1532139T1 (sl) 2007-10-31
WO2004011458A1 (en) 2004-02-05
US20080269511A2 (en) 2008-10-30
DK1532139T3 (da) 2007-10-15
AU2003248984A1 (en) 2004-02-16
DE60314426T2 (de) 2008-02-14

Similar Documents

Publication Publication Date Title
EP1117297A4 (en) ECTEINASCIDIN-743 SYNTHETIC ANALOGS
NO20012617L (no) Kinolin- og kinzolinderivater
CY1117132T1 (el) Παραγωγο θειαζολιου
DK0535231T3 (da) Pyrimidinnucleosid-derivater
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
DE69617909D1 (de) 2-substituierte vitamin-d3-derivate
MXPA03000341A (es) Derivados de variolina como agentes anit-cancer.
NO20040189L (no) Nye antitumorderivater av ET-743
WO2004014917A3 (en) Antitumoral analogs of lamellarins
NO20051037L (no) Totalsyntese av myriaporoner
NO20040113L (no) Variolinderivater og deres anvendelse som antitumormidler
ATE552003T1 (de) Chinoxalinderivate
ATE316524T1 (de) Oxy- und aminosubstituierte tetrahydrofurylderivate mit antitumoraktivität
DE69626624D1 (de) Medikamente gegen trhombocytopenie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application